ABSI vs CME

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Aug 23, 2026

ABSI

37.3
AI Score
VS
CME Wins

CME

37.7
AI Score

Investment Advisor Scores

ABSI

37score
Recommendation
SELL

CME

38score
Recommendation
SELL

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric ABSI CME Winner
Revenue 3.87M 3.59B CME
Net Income -74.12M 2.20B CME
Net Margin -1915.8% 61.2% CME
Operating Income -79.11M 2.42B CME
ROE -36.8% 8.3% CME
ROA -31.5% 1.1% CME
Total Assets 235.23M 194.68B CME
Cash 38.20M 2.14B CME
Current Ratio 5.63 1.02 ABSI
Free Cash Flow -55.82M 2.16B CME

Relative Price Performance (Last 90 Days)

ABSI 1M: +18.3% · 3M: +87.6% CME 1M: +8.1% · 3M: -4.9%

Current Technical Phase

ABSI

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (14.3% over 20 days), RSI 57

RSI (14): 56.6 · Price: $9.55

CME

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 65

RSI (14): 64.7 · Price: $274.98

Fundamentals Snapshot

Metric ABSI CME
Market Cap
Forward P/E -14.1 21.3
Trailing P/E 22.6
Revenue (TTM)
Revenue Growth -0.5% 0.0%
Gross Margin -54.0% 1.0%
Operating Margin -107.4% 0.7%
EPS -0.73 11.97
Dividend Yield 0.02%

Frequently Asked Questions

Based on our detailed analysis, CME is currently the stronger investment candidate, winning 9 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.